Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI-PROTECT: Prophylactic PPI in Lung Radiation
NCT07076914Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Panzobax, rabeprazole, lansoprazole in radiation-induced esophagitis. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Panzobaxrabeprazolelansoprazole
03
Conditions
radiation-induced esophagitis
Beyond the preview
Go deeper on NCT07076914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076914.